GGrantIndex
Sort

11,323 grants matching glioblastoma

Vulnerabilities of MMR-deficient glioblastoma

$387,027
Benjamin W. Purow · University Of Virginia · R01 · FY2024 · NS

Therapeutic resistance and aggressive malignancy in glioblastomas: the contribution of GTP metabolism through regulation by IMPDH2

$386,881
Atsuo Sasaki · University Of Cincinnati · R01 · FY2025 · CA

Metabolism Informs Intertumoral & Intratumoral Heterogeneity

$386,856
Jeremy N Rich · University Of California, San Diego · R01 · FY2018 · NS

Endothelial plasticity in glioma vascularization and therapy resistance

$386,788
Yi Fan · University Of Pennsylvania · R01 · FY2024 · NS

Defining the role of mutant IDH in glioma initiation and maintenance

$386,786
Sheri L. Holmen · University Of Utah · R01 · FY2011 · NS

Role of Parkinson's disease gene PARK2 in GBM oncogenesis and genomic instability

$386,750
Timothy An-Thy Chan · Sloan-Kettering Inst Can Research · R01 · FY2015 · NS

Role of Parkinson's disease gene PARK2 in GBM oncogenesis and genomic instability

$386,750
Timothy An-Thy Chan · Sloan-Kettering Inst Can Research · R01 · FY2013 · NS

Fluorescence lifetime technique for intraoperative identification of IDH mutations in brain cancer

$386,565
Laura Marcu · University Of California At Davis · R21 · FY2020 · CA

Detecting invading glioma cells through in vivo molecular imaging of the cell sur

$386,462
Susann M Brady-Kalnay · Case Western Reserve University · R01 · FY2011 · NS

A novel strategy to overcome the P-gp/BCRP drug efflux system at the blood-brain barrier to improve brain uptake of CNS therapeutics

$386,421
Bjoern Bauer · University Of Kentucky · R01 · FY2019 · NS

Neoantigen-specific Adoptive T Cell Therapy for Glioblastoma, IND-BB-13135, protocol submitted 04/25/2020

$386,381
Gary W. Wood · Tvax Biomedical, Inc. · R01 · FY2022 · FD

In vivo imaging of the stem cell loaded oncolytic viruses for cancer therapy

$386,339
Khalid A Shah · Brigham And Women'S Hospital · R01 · FY2018 · CA

In vivo SELEX strategies to identify potent aptamer-drug conjugates for glioblastoma

$386,233
Jann N Sarkaria · Mayo Clinic Rochester · R61 · FY2024 · NS

Controlled Release of Macromolecules

$386,153
Robert S Langer · Massachusetts Institute Of Technology · R37 · FY2011 · EB

The role of Nrf2 in mediating resistance to EGFR inhibition in glioblastoma

$386,138
Amyn Habib · Ut Southwestern Medical Center · R01 · FY2020 · CA

Elucidate and Modulate Cell Signaling in NK Cells for Glioma Treatment

$386,136
Jianhua Yu · Beckman Research Institute/City Of Hope · R01 · FY2018 · AI

Engineered and Encapsulated Stem Cells for Resected Brain Tumors

$386,033
Khalid A Shah · Brigham And Women'S Hospital · R01 · FY2020 · NS

Engineered and Encapsulated Stem Cells for Resected Brain Tumors

$386,033
Khalid A Shah · Brigham And Women'S Hospital · R01 · FY2019 · NS

Engineered and Encapsulated Stem Cells for Resected Brain Tumors

$386,033
Khalid A Shah · Brigham And Women'S Hospital · R01 · FY2021 · NS

Characterization of oncogenic FGFR3-TACC3 fusion gene in glioblastoma

$385,948
Wei Zhang · Wake Forest University Health Sciences · R01 · FY2016 · CA

Mechanisms of exRNA Trafficking

$385,935
Xandra Owens Breakefield · Massachusetts General Hospital · U19 · FY2016 · CA

Mechanisms of the Stromal Response to Smoothened Inhibition in Pancreatic Cancer

$385,747
Kenneth P Olive · Columbia University Health Sciences · R01 · FY2014 · CA

Regulation of Macrophage- and Microglia-mediated STING Signaling in Glioblastoma

$385,723
Rongze Olivia Lu · University Of California, San Francisco · R01 · FY2025 · NS

Brain tumor recurrence via signals from vascular endothelial cells

$385,704
Ichiro Nakano · University Of Alabama At Birmingham · R01 · FY2020 · NS

Neural Stem Cell Carriers for Glioblastoma Immunotherapy

$385,694
Irina V Balyasnikova · Northwestern University At Chicago · R21 · FY2018 · NS